Region Midtjylland

The Oncology Department at Region Midtjylland conducts studies focused on atherosclerotic cardiovascular disease and the prevention of recurrent ischemic events. Trials aim to test new oral agents that could lower the risk of major adverse cardiovascular events and improve safety for patients already on antiplatelet therapy.

• Evaluation of MK-0616 to reduce major adverse cardiovascular events in high‑risk individuals
• Testing the oral FXIa inhibitor asundexian for stroke prevention after acute non‑cardioembolic ischemic stroke or high‑risk TIA
• Safety assessment of major bleeding rates with asundexian compared to placebo in patients on antiplatelet therapy

With 64 investigators, the site supports robust cardiovascular research while maintaining patient‑centered care.

In the field of neoplasms, the center evaluates innovative treatment strategies for aggressive retroperitoneal sarcomas, including high‑risk de‑differentiated liposarcoma and leiomyosarcoma. The goal is to determine whether adding chemotherapy before curative‑intent surgery can improve disease‑free survival.

• Preoperative chemotherapy for high‑risk de‑differentiated liposarcoma and its impact on surgical outcomes
• Assessment of disease‑free survival benefits for patients with retroperitoneal leiomyosarcoma
• Comparative analysis of surgery alone versus surgery combined with neoadjuvant chemotherapy

The program reflects the department’s commitment to advancing cancer care through multidisciplinary collaboration.